Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

1.70USD
24 Mar 2017
Change (% chg)

$0.02 (+1.19%)
Prev Close
$1.68
Open
$1.65
Day's High
$1.73
Day's Low
$1.62
Volume
867,302
Avg. Vol
880,721
52-wk High
$1.81
52-wk Low
$0.51

Select another date:

Wed, Mar 15 2017

BRIEF-Catalyst Pharmaceuticals Q4 non-gaap loss per share $0.05 excluding items

* Catalyst pharmaceuticals announces fourth quarter and year-end 2016 financial results and provides corporate update

UPDATE 1-Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Catalyst Pharma's neuromuscular drug succeeds in study

Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

BRIEF-Catalyst Pharmaceuticals reports positive data from investigator-sponsored trial of firdapse

* Catalyst Pharmaceuticals announces positive data from investigator-sponsored trial of firdapse® in treating musk antibody positive myasthenia gravis

BRIEF-Biocept, Catalyst Pharma to provide liquid biopsy testing for small cell lung cancer

* Biocept and Catalyst Pharmaceuticals collaborate to provide liquid biopsy testing for small cell lung cancer to patients with Lambert Eaton Myasthenic Syndrome (LEMS)

BRIEF-Catalyst Pharmaceuticals announces Q3 2016 financial results

* Catalyst Pharmaceuticals-continues to believe currently available resources will be sufficient to complete development of Firdapse

BRIEF-Catalyst Pharmaceuticals gets FDA special protocol assessment for phase 3 trial of lems treatment

* Says intends to conduct its second phase 3 trial (designated as lms-003) at two clinical trial sites

Select another date:

More From Around the Web